Okay, let's tackle this question about competitive antagonism. The user wants a detailed explanation following their specific structure. First, I need to recall what competitive antagonism is. It's when an antagonist drug competes with an agonist for the same receptor site. The key points here are that the antagonist doesn't activate the receptor and can be overcome by increasing the agonist concentration.

The core concept should mention receptor occupancy and the fact that increasing agonist concentration can reverse the effect. Then, the correct answer would be something that contradicts these points. Let's think about the options. The question is asking for a false statement about competitive antagonism. Common false points might be that the antagonist doesn't affect the Emax (but actually, Emax remains the same, only EC50 shifts), or maybe that it doesn't cause a parallel shift in the dose-response curve. Wait, competitive antagonism does cause a rightward shift without changing Emax. So if an option says Emax decreases, that's false.

For the wrong options, they might include non-competitive antagonism features, like irreversible binding or non-parallel shifts. Also, maybe something about the antagonist's effect being permanent. Each incorrect option should be addressed with why it's not true for competitive antagonism.

The clinical pearl should highlight that Emax is unchanged and that increasing agonist can overcome the antagonist. The correct answer is the one that states something like the maximum effect is reduced, which is false because Emax stays the same. Let me structure this step by step, making sure each section is concise and fits under the character limit.

**Core Concept**
Competitive antagonism occurs when an antagonist competes with an agonist for the same receptor binding site. It does not alter the maximum effect (Emax) of the agonist but shifts the dose-response curve to the right, requiring higher agonist concentrations to achieve the same effect.

**Why the Correct Answer is Right**
The false statement is that competitive antagonism **reduces the maximum effect (Emax)** of the agonist. In reality, Emax remains unchanged because the antagonist does not occupy active receptor states; it only competes for binding. Increasing agonist concentration can overcome the antagonist, restoring the original Emax. This is distinct from non-competitive antagonism, which irreversibly reduces Emax.

**Why Each Wrong Option is Incorrect**
**Option A:** "Causes a rightward shift in the dose-response curve" – Correct for competitive antagonism.
**Option B:** "Can be overcome by increasing agonist concentration" – Correct for competitive antagonism.
**Option C:** "Does not bind irreversibly to receptors" – Correct, as competitive antagonists bind reversibly.

**Clinical Pearl / High-Yield Fact**
Remember: **"Right shift, no max loss"** – Competitive antagonists shift the curve right but preserve Emax. Contrast this with non-competitive antagonism, which lowers Emax irreversibly. Always check if a question mentions Emax changes to distinguish between mechanisms.

**Correct Answer: D. Reduces the maximum effect (Emax) of the agonist**

✓ Correct Answer: B. Efficacy decreases